Expression of HOXC9 and E2F2 are up-regulated in CD133+ cells isolated from human astrocytomas and associate with transformation of human astrocytes

Autor(es)

Okamoto, Oswaldo K. ^[1] ; Oba-Shinjo, Sueli M. ; Lopes, Luciana ; Marie, Suely K. Nagahashi ^[4]

Afiliação do(s) autor(es)

^[1] Sociedade Beneficente Israelita Brasileira Albert Einstein (SBIBAE). Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE) - Brasil

^[4] Universidade de São Paulo (USP). Faculdade de Medicina. Departamento de Neurologia - Brasil

• Tipo de documento: Artigo Científico
• Fonte: Biochimica et Biophysica Acta (BBA) : Gene Structure and Expression; v. 1769, n. 7/8, p. 437-442, July 2007.
• Área do conhecimento: Ciências da Saúde - Medicina
• Assunto(s): Neoplasias neuroepiteliomatosas Astrocitoma Glioblastoma Células-tronco neoplásicas

Resumo

Comparative analysis of cancer stem cells with their neoplastic and non-neoplastic counterparts should help better understand the underlying molecular events leading to transformation and tumor dissemination. Here, we report a molecular signature comprised by genes with exclusive aberrant expression in CD133+ cells, a reported subpopulation of tumorigenic stem-like cells, isolated from human glioblastomas. Microarrays covering 55,000 transcripts were used to compare gene expression profiles in purified subpopulations of CD133+ and CD133- GBM cells. Sixteen genes, many of which not previously associated with astrocytomas, were found aberrantly expressed in CD133+ cells, but not in CD133-, when compared with corresponding non-neoplastic controls. Up-regulation of two of such genes, E2F2 and HOXC9, was detected in a set of 54 astrocytomas of different grades and significantly associated with malignancy. Due to their distinctive expression in CD133+ cells, the use of E2F2 and HOXC9 as therapeutic targets for tumor eradication is suggested. (AU)

• Processo FAPESP: 02/01826-5 - Controle redox de expressão gênica: caracterização de redes regulatórias e seu envolvimento na diferenciação de células-tronco (stem cells)
• Beneficiário: Oswaldo Keith Okamoto
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 01/12898-4 - Genoma clínico
• Beneficiário: Suely Kazue Nagahashi Marie
• Modalidade de apoio: Auxílio à Pesquisa - Programa GENOMA